- Distal Filter Devices
- DistalÂ Occlusion Devices
- Proximal Occlusion Devices
The global embolic protection devices market is expected to grow at a CAGR of 8.6% over 2022-2028. Rising demand for minimally invasive procedures, funding and investments for R&D on embolic protection devices, favorable reimbursement policies for these systems, growing burden of chronic diseases, consumer awareness regarding embolic devices, rise in number of trans-catheter aortic valve replacement (TAVR) procedures Â and technological advancements in embolic protection devices are some key factors fostering the market growth. However, factors such as stringent regulatory scenario, high cost of the devices and presence of alternative treatment are hindering the market growth. In addition, high growth in emerging economies provides huge growth opportunity for the market. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and service providers engaged in global embolic protection devices products.
Fastest Growing Market
The growth of transcatheter aortic valve replacement (TAVR) has developed as a support for patients considered to be impossible offering together development in indications and statistically momentous mortality assistance. Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure to replace a narrowed aortic valve that fails to open properly. Rapid advances in technology have propelled TAVR to the forefront of treatment options. The initially reported periprocedural neurological events rates associated with transcatheter aortic valve replacement (TAVR) raised concerns that ultimately led to the development and to the clinical research of novel embolic protection devices (EPD). Embolic protection devices in TAVR appear to reduce the 30-day risk of stroke but do not affect 30 day mortality.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.